Terms: = Prostate cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Diagnosis
260 results:
1. Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study.
Zhu M; Fu Q; Zang Y; Shao Z; Zhou Y; Jiang Z; Wang W; Shi B; Chen S; Zhu Y
Urol Oncol; 2024 May; 42(5):159.e17-159.e23. PubMed ID: 38480077
[TBL] [Abstract] [Full Text] [Related]
2. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life.
Smani S; Novosel M; Sutherland R; Jeong F; Jalfon M; Marks V; Rajwa P; Nolazco JI; Washington SL; Renzulli JF; Sprenkle P; Kim IY; Leapman MS
Urol Oncol; 2024 Feb; 42(2):28.e9-28.e20. PubMed ID: 38161105
[TBL] [Abstract] [Full Text] [Related]
3. Can MRI Help Inform Which Men With a History of Multifocal High-Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant prostate cancer?
Sessine MS; Radoiu CS; Qi J; Labardee C; Burks F; George AK; Lane BR; Lim K; Dabaja A; Morgan TM; Cher ML; Semerjian AM; Ginsburg KB
J Urol; 2024 Feb; 211(2):234-240. PubMed ID: 37930976
[TBL] [Abstract] [Full Text] [Related]
4. Extracellular vesicle biomarkers for prostate cancer diagnosis: A systematic review and meta-analysis.
Li Y; Shi X; Jia E; Qin S; Yu F
Urol Oncol; 2023 Nov; 41(11):440-453. PubMed ID: 37914569
[TBL] [Abstract] [Full Text] [Related]
5. Development and evaluation of the MiCheck® prostate test for clinically significant prostate cancer.
Shore ND; Polikarpov DM; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Levin RA; Wissmueller S; Le TH; Gillatt DA; Chan DW; Deng N; Siddireddy JS; Lu Y; Campbell DH; Walsh BJ
Urol Oncol; 2023 Nov; 41(11):454.e9-454.e16. PubMed ID: 37734979
[TBL] [Abstract] [Full Text] [Related]
6. Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative.
Chandrasekar T; Denisenko A; Mico V; McPartland C; Shah Y; Mark JR; Lallas CD; Fonshell C; Danella J; Jacobs B; Lanchoney T; Raman JD; Tomaszewski J; Reese A; Singer EA; Ginzburg S; Smaldone M; Uzzo R; Guzzo TJ; Trabulsi EJ
Urol Oncol; 2023 Aug; 41(8):355.e1-355.e8. PubMed ID: 37357123
[TBL] [Abstract] [Full Text] [Related]
7. Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for prostate cancer (cap).
Thorn JC; Turner EL; Walsh EI; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM
BMC Health Serv Res; 2023 Jun; 23(1):610. PubMed ID: 37296430
[TBL] [Abstract] [Full Text] [Related]
8. Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential.
Ragavi R; Muthukumaran P; Nandagopal S; Ahirwar DK; Tomo S; Misra S; Guerriero G; Shukla KK
Urol Oncol; 2023 Aug; 41(8):340-353. PubMed ID: 37032230
[TBL] [Abstract] [Full Text] [Related]
9. Biomarkers of Aggressive prostate cancer at diagnosis.
Boehm BE; York ME; Petrovics G; Kohaar I; Chesnut GT
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768533
[TBL] [Abstract] [Full Text] [Related]
10. Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations.
Nguyen DD; Labban M; Briggs L; Wallis CJD; Cole AP; Lipsitz SR; Iyer HS; Rebbeck TR; Weissman JS; Choueiri TK; Trinh QD
Urol Oncol; 2023 May; 41(5):252.e9-252.e17. PubMed ID: 36759298
[TBL] [Abstract] [Full Text] [Related]
11. Characteristics of BRCA2 Mutated prostate cancer at Presentation.
Han H; Park CK; Cho NH; Lee J; Jang WS; Ham WS; Choi YD; Cho KS
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362213
[TBL] [Abstract] [Full Text] [Related]
12. Free-indocyanine green-guided pelvic lymph node dissection during radical prostatectomy.
Claps F; de Pablos-Rodríguez P; Gómez-Ferrer Á; Mascarós JM; Marenco J; Collado Serra A; Casanova Ramón-Borja J; Calatrava Fons A; Trombetta C; Rubio-Briones J; Ramírez-Backhaus M
Urol Oncol; 2022 Nov; 40(11):489.e19-489.e26. PubMed ID: 36175317
[TBL] [Abstract] [Full Text] [Related]
13. Natural History of Patients with prostate MRI Likert 1-3 and Development of Roscap: a Multivariate Risk Score for Clinically Significant cancer.
Orecchia L; Nardi A; Fletcher P; Ippoliti S; Grounds J; Dokubo I; Spicchiale CF; Miah S; Miano R; Barrett T; Kastner C
Clin Genitourin Cancer; 2023 Feb; 21(1):162-170. PubMed ID: 35970760
[TBL] [Abstract] [Full Text] [Related]
14. METTL3 preferentially enhances non-m
Wei X; Huo Y; Pi J; Gao Y; Rao S; He M; Wei Q; Song P; Chen Y; Lu D; Song W; Liang J; Xu L; Wang H; Hong G; Guo Y; Si Y; Xu J; Wang X; Ma Y; Yu S; Zou D; Jin J; Wang F; Yu J
Nat Cell Biol; 2022 Aug; 24(8):1278-1290. PubMed ID: 35927451
[TBL] [Abstract] [Full Text] [Related]
15. prostate cancer screening - is it time to change approach?
Vargovčák M; Dorko E; Rimárová K; Knap V
Cent Eur J Public Health; 2022 Jun; 30(Supplement):S11-S15. PubMed ID: 35841219
[TBL] [Abstract] [Full Text] [Related]
16. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Urol Oncol; 2022 Sep; 40(9):407.e9-407.e19. PubMed ID: 35817649
[TBL] [Abstract] [Full Text] [Related]
17. [Comparison of systematic, targeted and combined prostate biopsies for the diagnosis of prostate cancer with MRI lesion].
Gander J; Guandalino M; Vedrine N; Charbonnel C; Gayrel P; Ceruti F; Guy L
Prog Urol; 2022 Oct; 32(12):836-842. PubMed ID: 35577670
[TBL] [Abstract] [Full Text] [Related]
18. Recreational and occupational physical activity in relation to prostate cancer aggressiveness: the North Carolina-Louisiana prostate cancer Project (Pcap).
Steck SE; Su LJ; Antwi SO; Morris BB; Crawford B; Adams SA; Hebert JR; Fontham ETH; Bensen JT; Mohler JL; Arab L
Cancer Causes Control; 2022 Jun; 33(6):875-887. PubMed ID: 35320830
[TBL] [Abstract] [Full Text] [Related]
19. RNA-based biomarkers for the diagnosis, prognosis, and therapeutic response monitoring of prostate cancer.
Bae J; Yang SH; Kim A; Kim HG
Urol Oncol; 2022 Mar; 40(3):105.e1-105.e10. PubMed ID: 34952790
[TBL] [Abstract] [Full Text] [Related]
20. A constructivist grounded theory study on decision-making for treatment choice among Black African and Black Caribbean prostate cancer survivors.
Bamidele OO; McCaughan E
Eur J Cancer Care (Engl); 2022 Jan; 31(1):e13516. PubMed ID: 34632651
[TBL] [Abstract] [Full Text] [Related]
[Next]
